Radiomer Therapeutics

Executive Summary

Radiomer Therapeutics is a preclinical-stage biotechnology company developing a new class of targeted radiopharmaceuticals called Radiomers for cancer theranostics. Founded in 2022 and headquartered in Cambridge, MA, the company leverages its proprietary Raptamer platform—a novel peptide-oligonucleotide hybrid targeting vector—to create radioligand therapies with high specificity and favorable pharmacokinetics. By combining the targeting precision of peptides with the stability and tunability of oligonucleotides, Radiomer aims to overcome limitations of traditional antibody- and peptide-based radioconjugates, such as poor tumor penetration and rapid clearance. The company's initial focus is on established and novel solid tumor targets, positioning it in the rapidly growing radiopharmaceutical field. As a private, early-stage entity, Radiomer has not disclosed funding amounts or clinical pipeline details, suggesting it is likely in lead optimization and preclinical validation. The success of its platform hinges on demonstrating in vivo proof-of-concept and differentiating its technology from competitors like Novartis' Pluvicto and emerging platforms such as radiolabeled antibodies or small molecules. If successful, Radiomer could address significant unmet needs in targeted alpha- and beta-therapy, offering potential for improved efficacy and reduced off-target toxicity. However, the company faces typical early-stage risks, including technical validation, manufacturing scalability, and capital requirements to advance toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data in Animal Models40% success
• Q2 2027Series A Financing or Notable Partnership60% success
• Q3 2027IND-Enabling Studies Initiation for Lead Candidate35% success